1. Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption;JL Rubenstein;Neoplasia,2000
2. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors;AD Laird;Cancer Res,2000
3. Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2;P Kunkel;Cancer Res,2001
4. PTK787/ZK222584, an inhibitor of vascular endothelial growth factor receptor tyrosine kinases, decreases glioma growth and vascularization;RH Goldbrunner;Neurosurgery,2004
5. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types;TA Fong;Cancer Res,1999